Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Christopher J. Sobecki acquired 25,000 shares of the stock in a transaction dated Monday, September 16th. The stock was bought at an average price of $2.55 per share, for a total transaction of $63,750.00. Following the purchase, the director now owns 112,493 shares of the company’s stock, valued at approximately $286,857.15. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of Lexicon Pharmaceuticals stock opened at $3.45 on Friday. The company’s fifty day simple moving average is $1.58 and its 200-day simple moving average is $4.92. The company has a market cap of $312.44 million, a price-to-earnings ratio of -3.03 and a beta of 0.75. Lexicon Pharmaceuticals, Inc. has a 1 year low of $1.13 and a 1 year high of $11.51.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.13). The firm had revenue of $9.68 million for the quarter, compared to analyst estimates of $28.52 million. During the same quarter last year, the firm posted ($0.33) EPS. The company’s revenue was down 29.9% compared to the same quarter last year. On average, analysts anticipate that Lexicon Pharmaceuticals, Inc. will post 0.69 earnings per share for the current year.
LXRX has been the topic of several research analyst reports. G.Research upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Citigroup lowered their price objective on shares of Lexicon Pharmaceuticals from $15.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, July 30th. ValuEngine downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. Stifel Nicolaus downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $10.00 to $4.00 in a research note on Monday, July 29th. Finally, Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $6.70.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Recommended Story: Stop Order
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.